ArticleInternational journal of nanomedicine2026
Sequential Barrier Navigation by Yeast β-Glucan-Engineered Liposomal Nanovaccines Potentiates Oral Melanoma Immunotherapy.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Orally delivered protein antigens face gastrointestinal degradation and inefficient transport through mucus, across the intestinal epithelium, and into antigen-presenting cells (APCs). To address these barriers, we developed YGB@OVA/PBA-C-LIPs, an ovalbumin (OVA)-loaded cationic liposomal nanovaccine coated with yeast β-glucan (YGB) and functionalized with phenylboronic acid (PBA). Methods: We characterized the physicochemical properties of YGB@OVA/PBA-C-LIPs and evaluated their mucus and epithelial transport, macrophage uptake, OVA cross-presentation, and immune activation in vitro. Laminarin competition was used to assess β-glucan-sensitive uptake. Gastrointestinal residence, immune responses, antitumor activity, and tolerability were examined after oral administration to B16-OVA-bearing mice. Results: YGB@OVA/PBA-C-LIPs averaged 127.5 ± 0.8 nm in diameter and had an OVA encapsulation efficiency of 83.17 ± 1.98%, with no marked size increase over 12 days at 4 °C. They improved transport through a simulated mucus layer and across the Caco-2/Raji B model and increased RAW264.7 macrophage uptake; laminarin attenuated this advantage, supporting a β-glucan-sensitive component of uptake. The formulation also increased surface CD80 and H-2K Conclusion: The YGB/PBA dual-functionalized formulation combined gastrointestinal protection and mucosal transport with enhanced antigen presentation by APCs, improving immune responses and tumor control in the B16-OVA model. Validation with clinically relevant tumor antigens is needed to establish broader therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.